Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

10.44

Mkt cap

365M

Volume

71K

High

10.63

P/E Ratio

-5.38

52-wk high

16.08

Low

10.35

Div yield

N/A

52-wk low

6.76

Nyxoah SA held its Q4 2024 earnings call, discussing financial results and company performance. Key participants included the CFO and CEO, with analysts from major firms attending.

Portfolio Pulse from

March 13, 2025 | 9:00 pm

Nyxoah SA (NYXH) reported a Q4 loss of $0.49 per share, slightly better than the Zacks Consensus Estimate of a $0.50 loss. However, this is a larger loss compared to the $0.41 per share loss from the previous year.

Portfolio Pulse from

March 13, 2025 | 12:30 pm

Nyxoah SA reported its financial and operating results for Q4 and FY 2024, with a focus on its upcoming U.S. commercial launch in March 2025. The FDA PMA application review is nearing completion.

Portfolio Pulse from

March 13, 2025 | 6:15 am

Nyxoah is set to release its fourth quarter and full-year 2024 financial results on March 13, 2025. This announcement is crucial for investors to assess the company's financial health and performance over the past year.

Portfolio Pulse from

March 10, 2025 | 9:15 pm

Nyxoah will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which could provide exposure and networking opportunities for the company.

Portfolio Pulse from

March 03, 2025 | 9:45 pm

Nyxoah has announced the commercial launch of its Genio® Breakthrough Therapy in the Middle East, with the first patient implanted at Saudi German Hospital in Dubai, UAE.

Portfolio Pulse from

February 19, 2025 | 6:15 am

Nyxoah has announced the commercial launch of its Genio® Breakthrough Therapy in the Middle East, with the first patient implanted at Saudi German Hospital in Dubai, UAE.

Portfolio Pulse from

February 19, 2025 | 6:15 am

Nyxoah SA announced receiving a transparency notification from BlackRock, Inc. regarding large shareholdings, as per regulatory requirements.

Portfolio Pulse from

January 20, 2025 | 9:45 pm

Nyxoah's Genio implant is set to transform Obstructive Sleep Apnea treatment, with FDA approval anticipated in Q1 2025. This approval could significantly boost Nyxoah's revenue and share price, despite the company's high burn rate.

Portfolio Pulse from

December 30, 2024 | 9:15 am

Nyxoah SA announced receiving a transparency notification from BlackRock, Inc. regarding large shareholdings, as per regulatory requirements.

Portfolio Pulse from

December 20, 2024 | 9:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.